Kornimate/medical-research-clean huggingface dataset:
arterial destiffening effects of sglt2 inhibition in veterans with obesity

Conditions: Obesity; Vascular Health

Summary: the study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. the goal of the study is to determine the effects of empagliflozin on arterial health in veterans with obesity.

the investigators will employ a double-blinded randomized placebo-controlled trial to determine the effects of 12 weeks of sglt2 inhibition with empagliflozin (10mg daily), or matching placebo, on arterial stiffness in veterans with obesity. fifty veterans with obesity (bmi 30-45kg/m2), 30-60 years of age, will be recruited from the harry s. truman memorial va hospital in columbia, missouri.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) 30-45 kg/m2 * 30-60 years of age at randomization * evidence of arterial stiffening (defined as carotid femoral pwv\>age-predicted) at screening visit (pmid: 20530030) exclusion criteria: * unable to provide consent * diabetes mellitus * uncontrolled hypertension (\>180/90mmhg) or systolic \<100mmhg at screening visit * known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke * diagnosis of chronic kidney disease * active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) * excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women) * use of glp-1 analogs or sglt2 inhibitors * use of hormone replacement therapy * use of pharmacological therapy for weight loss * body weight changes \>10% within the past 6 months * history of hypersensitivity to nitrates * history of ketoacidosis * history of recurrent utis or mycotic genital infections * use of anticoagulants * change in anti-hypertensive medication regimen (if in use) during the last 90 days * pregnancy
efficacy and patient satisfaction of miralax and gatorade versus movi prep

Conditions: Colorectal Cancer

Summary: this study will be comparing patient satisfaction, efficacy comparing miralax with gatorade versus movi prep for outpatient colonoscopy.

study is the purpose of evaluating patient satisfaction and at the same time efficacy of the bowel regimen in cleansing the colon

Eligibility criteria:
inclusion criteria: * outpatient colonoscopy for screening for other gi related problems exclusion criteria: * severe congestive heart failure (chf), * chronic kidney disease (ckd), * less than age 18 or more than 80 years

Keywords: miralax with gatorade and dulcolax movi pre patient satisfaction and efficacy
transcatheter aortic valve replacement in severe low flow, low gradient aortic stenosis

Conditions: Low Flow, Low Gradient Aortic Stenosis

Summary: low-tavr is a real-world, retrospective and prospective, multicenter italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis undergoing transcatheter aortic valve replacement (tavr) and, in particular: * risk factors * gender differences * comorbidities * pharmacological treatment * tavr procedural characteristics * periprocedural and in-hospital complications * clinical outcome at 30-day, 1-year, 2-year and 5-year follow-up

low-tavr is a real-world, retrospective and prospective, multicenter italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis (lflg-as) undergoing transcatheter aortic valve replacement (tavr). the register aims to include at least 1,500 patients diagnosed with lflg-as undergoing tavr at the participating centres. the inclusion criteria are: * lflg-as diagnosis according to current european society of cardiology guidelines * age 18 years or older * written informed consent the exclusion criteria are: * lflg-as pseudo-severe or non-confirmed severe aortic stenosis * lflg-as referred for medical treatment or undergoing surgery clinical outcome is evaluated at a 30-day, 1-year, 2-year, and 5-year follow-up. the primary endpoint of interest of the registry is the assessment of the incidence of the composite of all-cause mortality and hospitalization for heart failure at one year. the secondary endpoints are the assessment of: * periprocedural tavr complications: complete atrioventricular block, stroke, acute myocardial infarction, acute aortic insufficiency, cardiogenic shock, acute pulmonary edema, cardiac tamponade, aortic rupture; * adverse events during hospitalization: major and minor bleeding, major and minor vascular complications, definitive pacemaker implantation, cardiogenic shock, myocardial infarction, stroke, and death; * adverse events at 30 days, one year, two years, and five years: all-cause mortality, hospitalizations for heart failure, cardiovascular mortality, myocardial infarction, stroke, major and minor bleedings.

Eligibility criteria:
inclusion criteria: * lflg-as diagnosis according to current european society of cardiology guidelines * age 18 years or older * written informed consent exclusion criteria: * lflg-as pseudo-severe or non-confirmed severe aortic stenosis * lflg-as referred for medical treatment or undergoing surgery

Keywords: aortic stenosis transcatheter aortic valve replacement clinical outcomes interventional cardiology
stepped care for patients to optimize whole recovery

Conditions: Opioid Use Disorder; Chronic Pain

Summary: this is a prospective, randomized clinical trial of 204 patients with opioid use disorder (oud) and chronic pain (cp) to test the effectiveness of treatment as usual compared with stepped care for patients to optimize whole recovery (sc-powr) to reduce pain interference (aim 1) and decrease illicit opioid use, alcohol use, anxiety, depression, and stress, and improve sleep (aim 2). eligible participants will begin medications for opioid use disorder (moud) and will be randomized to receive sc-powr (i.e., cognitive behavioral therapy (cbt), moud, and onsite groups for exercise \[wii fit, tai chi\] and stress reduction \[relaxation training, auricular acupuncture\] for 24 weeks. participants will be followed for another 24 weeks to evaluate durability of treatment response on pain interference illicit opioid use, alcohol use, anxiety, depression, stress, sleep, and retention in moud (aim 3).

participants who meet criteria for cp and oud (n=204) will be initiated onto moud and randomized to 24 weeks of either treatment as usual (tau) or 24 weeks of sc-powr. sc-powr patients will be "stepped up" according to a priori criteria. patients randomized to sc-powr will receive a behavioral intervention consisting of 12 cognitive behavioral therapy (cbt) sessions over a 24-week period involving improvements in substance use and pain since baseline. following 24 weeks of sc-powr, patients are offered once monthly peer-support groups.

Eligibility criteria:
inclusion criteria: * seeking treatment at apt foundation * receiving medications for opioid use disorder (moud provided by apt) * have high impact chronic pain (\>= 3 months duration of pain occurring most days which limits life or work activities and/or leads to inability to work) * meet dsm-5 criteria for moderate to severe oud * in the past 2 months, has an opioid-positive urine test or self-reports opioid use * understand english * able to provide informed consent exclusion criteria: * have pending surgery or invasive pain management procedure * acutely psychotic, suicidal, or homicidal * psychiatric instability (e.g., recent suicide attempt) * have a contraindication to exercise (e.g. complete heart block) * have a pending or planned relocation or pending incarceration
the impact of experienced endoscopy nurse participation on polyp and adenoma detection during colonoscopy

Conditions: Polyp; Adenoma

Summary: the purpose of this study is to determine whether experienced endoscopy nurse participation during screening colonoscopy could increase polyp and adenoma detection rate.


Eligibility criteria:
inclusion criteria: * age 40-70 average risk screening colonoscopy exclusion criteria: * gi bleeding ; * history of colorectal surgery ; * inflammatory bowel disease ; * colorectal cancer,or polyposis syndrome

Keywords: nurse; colonoscopy; polyp; adenoma;
compare diagnostic performance of dixon &chess sequences calculating ramris score in early rheumatoid arthritis.

Conditions: Arthritis, Rheumatoid

Summary: in a preliminary mri study of healthy volunteers's hands investigators showed that the suppression of the fat signal obtained by the dixon sequences is greater than that obtained by the "classic" chess sequences with a better t1-weighted image quality. the investigators goal now is to compare these sequences in the quantification of the inflammatory activity of rheumatoid arthritis by the ramris score. to investigators knowledge, only one study compared those two types of sequence with many limitations including a limited number of patients included.

rheumatoid arthritis (ra) is the most common chronic inflammatory arthropathy and it mostly affect young women. the mri sequences currently validated for the joint inflammation assessment are the fat-suppressed sequences produced either by spectral presaturation (chess sequences) or by inversion-recovery (stir = short tau inversion recovery sequence). the presaturation sequences outweigh the stir sequence due to higher spatial resolution at the expense of sometimes more random saturation of the fat signal. recently, a third method of suppressing the fat signal (dixon method) has reappeared thanks to advances in computing power (post-processing). in a preliminary mri study of the hands of healthy volunteers, the investigators showed that the suppression of the fat signal obtained by the dixon sequences is greater than that obtained by the "classic" chess sequences in t1 and t2 weighting with better quality. image in t1 weighting. this increased performance, particularly in terms of fat suppression, could lead to better detection of pr lesions on mri.

Eligibility criteria:
inclusion criteria: * - rheumatoid arthritis diagnosis for less than 3 years exclusion criteria: * contraindication to dotarem contrast injection * contraindication to mri due to incompatible implanted material (peacemaker, prosthesis,...)
effect of kinetic control training on pain and craniovertebral angle in symptomatic forward head posture

Conditions: Symptomatic Forwardhead Posture

Summary: the goal of this clinical trial is to investigate the effect of adding kinetic control training of cervical and shoulder joints on pain, neck function, neuromuscular control of the deep cervical flexors, and craniovertebral angle in symptomatic forward head posture.

forward head posture (fhp) is one of the most common postural deformity, which affects 66% of the patient population with high prevalence among university students due to prolonged usage of computer, smartphones and faulty posture during lectures with lack of awareness about proper posture among them.participants with fhp exhibited abnormal sensorimotor control and autonomic nervous system dysfunction compared to those with normal head alignment . identifying and classifying movement faults is fast becoming the key of recent neuromusculoskeletal rehabilitation. uncontrolled movement (ucm), contributing to neck pain symptoms, can cause compression or impingement on one side of joints while developing tensile strain on the other side. if ucm is not managed, and the related tissue stress and strain are sustained or repeated beyond the limits of tissue tolerance, multiple tissue pathology may develop eventually and a combination of symptoms may occur . as seen in symptomatic forward head posture. along with the identification of site and direction of the faults, direction-movement control intervention(kinetic control) retrains the control of the movement faults. the suggestion is that uncontrolled movement links to the pattern of movement during everyday activities and relates to neck pain. this maneuver can reduce symptoms of neck pain.

Eligibility criteria:
inclusion criteria: * 1) 50 subjects of both genders aged 18-40 years old with symptomatic forward head posture (fhp) and body mass index (bmi) less than 30 kg/m2 . 2) subjects have fhp if cva ≤ 50° for assessing fhp 3) pain between three and eight using numerical pain rating scale nprs 4) subjects have non-specific neck pain for at least 3 months exclusion criteria: * the patients were excluded if they had: 1. experienced a history of neck injuries, neck and shoulder surgery 2. shoulder trauma, tendinitis, thoracic surgery 3. neurological disorders such as cervical spondylosis, spondylolisthesis. 4. disc prolapse 5. rheumatic disease, fibromyalgia
effectiveness of warm saline distension media on relieving pain in office hysteroscopy

Conditions: Hysteroscopy

Summary: the aim of the study is to compare the effectiveness of warm saline distension media versus room temperature saline distension media on relieving pain in office hysteroscopy .

research hypothesis : in women undergoing diagnostic hysteroscopy, warm saline distension media may be effective in decreasing the pain during the procedure . research question : in women undergoing diagnostic hysteroscopy, does warm saline distension media decrease the pain during the procedure ? aim of the work : - this study aim to assess the efficacy of warm saline distension media in decreasing the pain in women undergoing diagnostic hysteroscopy

Eligibility criteria:
inclusion criteria: 1. age: 20-40 years old (premenopausal women ). 2. normal cervical morphology during speculum examination. 3. women complaining of abnormal uterine bleeding 4. women underging the procedure to evaluate the endocervical canal, uterine cavity and tubal ostia because of infertility. 5. suspected mullerian anomalies. exclusion criteria: * a. pregnancy. b. suspected acute pelvic inflammatory disease. c. past history of medical disorders, especially associated with neuropathies, e.g. diabetes, chronic kidney disease, etc. d. history of vaginal pruritis, discharge, dysuria, dysmenorrhea, dyspareunia or chronic pelvic pain. e. presence of pain, profuse bleeding or other symptoms at the time of the procedure. f. history of uterine surgery that occurred less than 1 month previously. g. history of previous cervical procedures. h. administration of general, cervical or paracervical anesthesia. i. administration of sedatives. j. any use of analgesic agents before the procedure. k. cervical preparation by misoprostol before procedure orally or vaginally for cervical ripening to improve the likelihood of successful cervical dilation and decrease intraoperative pain . l. need for cervical dilatation during procedure. m. need for biopsy or any operative intervention during the procedure.
phase i study of opc-61815

Conditions: Congestive Heart Failure

Summary: to investigate the effects of intravenous administration of opc-61815 at 16 and 32 mg on qt/qtc interval in healthy male subjects


Eligibility criteria:
inclusion criteria: * body mass index (bmi) \[body weight in kg / (height in m)2\] of at least 18.5 kg/m2 and less than 25.0 kg/m2 as a result of at the screening examination * judged by the investigator or subinvestigator to be capable of providing written informed consent prior to start of any trial-related procedures and capable of complying with the procedures for this trial exclusion criteria: * subjects with a medical history of convulsive disorder, long qt syndrome (including family history), syncope during swimming, or any other type of syncope or cryptogenic loss of consciousness * subjects with a serum electrolyte abnormality (hypokalemia, hypomagnesemia, hypocalcemia, etc) * subjects with a family history of sudden death
correlation between pelvic pain, low back pain, and postural stability in healthy young women during the menstrual cycle

Conditions: Pain, Menstrual

Summary: the menstrual cycle is governed by hormonal changes. each cycle can be divided into three phases based on events in the ovary (ovarian cycle) or in the uterus (uterine cycle). h0: there will be no correlation between pelvic pain and postural stability in healthy young women during the menstrual cycle h0: there will be no correlation between low back pain and postural stability in healthy young women during the menstrual cycle h0: there will be no correlation between pelvic pain and low back pain in healthy young women during the menstrual cycle

thirty-five female patients participated in this study. they were randomly assigned to the study. the outcome measures were pelvic pain assessed using the functional pelvic pain scale, low back pain assessed using the back pain functional scale, and postural stability assessed using the biodex balance system.

Eligibility criteria:
inclusion criteria: 1. all young females will suffer from pelvic pain, low back pain, and postural instability during the menstrual cycle 2. age will range from 18 to 22 years 3. all young females will have a bmi range from 25-30 exclusion criteria: 1. lumbar spondylosis 2. lumbar disc prolapse 3. sacroiliac joint arthritis 4. low back trauma 5. bmi more than 30

Keywords: pelvic pain, low back pain postural stability, and menstrual cycle
long-term study of ciclosporin for atopic dermatitis

Conditions: Severe Atopic Dermatitis

Summary: in patients with severe adult atopic dermatitis, the safety and efficacy of ol27-400mepc will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment


Eligibility criteria:
inclusion criteria: * - appropriate the definition/diagnosis criteria of atopic dermatitis of the japanese dermatological association * patients with severest atopic dermatitis \[according to the "guidelines for treatment of atopic dermatitis 2002, the severity of atopic dermatitis will be classified as severest when an eruption associated with severe inflammation (a lesion associated with erythema, papule, erosion, infiltration, lichenification, etc.) is noted on at least 30% of body surface on the day of subject enrollment\]. exclusion criteria: * patients who received oral preparations, injections, inhaled preparations and suppositories of steroids or immunosuppressants other than tacrolimus hydrate ointments within 14 days of subject enrollment * patients who might receive the oral/injection drugs which are known to enhance nephrotoxicity, increase serum potassium levels, hmg-coa reductase inhibitors or theophylline during the treatment period. * patients who received or are receiving an ultraviolet therapy (puva therapy, etc.) * patients with hypertension, active infectional disease, gout etc. other protocol-defined exclusion criteria may apply.

Keywords: atopic dermatitis, ciclosporin,
dvt ultrasound in the emergency department

Conditions: Deep Vein Thrombosis; DVT

Summary: emergency medicine (em) residents routinely conduct bedside ultrasound exams in the emergency department (ed) employing the two point compression method. this study endeavors to investigate the accuracy and utility of bedside ultrasound for deep vein thrombosis (dvt) in the ed by em residents by comparing the results of that exam against the gold standard of a dvt ultrasound performed in the radiology department and interpreted by a radiologist.

for subjects with suspicion of dvt to the emergency department, an em resident will perform a bedside non-diagnostic two point compression dvt ultrasound. subjects will then receive a diagnostic dvt ultrasound in the radiology department with official radiologist interpretation. the bedside ultrasound will not interfere with or delay the diagnostic ultrasound. patient demographic and clinical data will be collected for validation purposes. validation of the the em resident interpretation will be accomplished by comparison to the official radiologist interpretation.

Eligibility criteria:
inclusion criteria: * age 18 or older * suspect of having dvt exclusion criteria: * known dvt * dvt with in previous 6 months * dvt ultrasound within the last 6 months

Keywords: deep vein thrombosis dvt leg swelling leg pain blood clot
parkinson's foundation surveys

Conditions: Parkinson Disease

Summary: parkinson's foundation surveys is an initiative seeking to periodically survey people with parkinson's disease (pd), their care partners and medical professionals to better understand specific aspects of living with pd.


Eligibility criteria:
inclusion criteria: * willingness to be contacted by the parkinson's foundation for surveys and any future research opportunities * anyone who self-reports that they have a diagnosis of parkinson's disease * care partner of a person with parkinson's disease * any health professional that regularly works with people with parkinson's disease * 18 years of age or older exclusion criteria: * people who report that they do not have a diagnosis of parkinson's disease, are not a care partner to someone with pd or do not work with people with pd in the health setting * an individual younger than 18 years of age
aged diagnostics liver disease assessment

Conditions: NASH With Fibrosis; NAFLD; Healthy

Summary: continue development of previously established methods to further validate candidate biomarkers that can discriminate steatosis from nash and separately stage fibrosis from blood. the first assessment is to conduct test method verification to expand sample size to several hundred samples through whole genome sequencing methods. the second assessment is focused on biomarker validation by comparing targeted sequencing from patient plasma. several sub- assessments will be conducted to support overall biomarker development efforts.

aim 1: test method verification, whole genome bisulfite sequencing assessment for liver tissue and plasma conduct whole genome bisulfite sequencing in patient liver tissue and patient plasma to identified candidate biomarkers that can discriminate between steatosis and nash, and separately conduct a comparative analysis of patient liver tissue and patient plasma samples to assess nash encompassing nash with mild fibrosis, nash with significant fibrosis and nash with advanced fibrosis. the purpose of each is to identify a set of markers that have biological relevance on the liver and then identify epigenetic biomarkers in plasma derived from liver tissue. note: both a subset of nash specific biomarkers and fibrosis specific biomarkers have been previously reported for technical feasibility. aim 2: biomarker validation, targeted epigenetic sequencing assessment select top nash specific biomarkers and top fibrosis specific biomarkers and design, develop and test probes to assess overall performance of each candidate biomarker in plasma. conduct comparative analysis between various targeted sequencing and pcr based modalities. candidate biomarker performance will be evaluated based on sensitivity, specificity, auroc and reproducibility, among several other assessments.

Eligibility criteria:
inclusion criteria: * participant with liver biopsy over the past 1-2 years are permissible for study inclusion. * participant is considered to be a "healthy subject" relative to any form of liver disease or * participant is suspected of having one of the following diagnoses: metabolic syndrome, nafld, fibrosis/cirrhosis, cardiovascular disease, chronic kidney disease. exclusion criteria: * participant is known to have hiv, hepatitis b or hepatitis c * participant has any other known form of chronic liver disease (aside from nafld/liver fibrosis) * participant has excess alcohol intake, excess alcohol is defined as participants that exceed an average 20g of alcohol daily for females (140g weekly intake) and average 30g of alcohol daily for males (210g weekly intake) * participant has had a bone marrow transplant at any time * participant is on anti-coagulation or anti-platelet therapy * participant is known to be pregnant * participant is unable to provide informed consent